EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DMK Pharmaceuticals's enterprise value is $0.02 Mil.
DMK Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-16.72 Mil. Therefore, DMK Pharmaceuticals's EV-to-EBITDA for today is -0.00.
The historical rank and industry rank for DMK Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of DMK Pharmaceuticals was 0.38. The lowest was -7.83. And the median was -2.18.
DMKPQ's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 13.805 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), DMK Pharmaceuticals's stock price is $0.0503.
DMK Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.580. Therefore, DMK Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
DMK Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for DMK Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
DMK Pharmaceuticals Annual Data
Trend
Mar13
Mar14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
EV-to-EBITDA
-2.48
-1.58
-1.28
-2.22
-1.05
DMK Pharmaceuticals Quarterly Data
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
EV-to-EBITDA
-1.14
-1.05
-0.82
-0.33
-0.02
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's EV-to-EBITDA falls into.
DMK Pharmaceuticals EV-to-EBITDA Calculation
DMK Pharmaceuticals's EV-to-EBITDA for today is calculated as:
DMK Pharmaceuticals's current Enterprise Value is $0.02 Mil.
DMK Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
DMK Pharmaceuticals's PE Ratio for today is calculated as:
DMK Pharmaceuticals's share price for today is $0.0503.
DMK Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of DMK Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 